{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-050995","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2023-10-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.892968+00:00","generated_at":"2026-06-10T06:22:47.778457+00:00","sec_items":["8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"low","headline":"Ovid Therapeutics posts R&D Day corporate presentation; no financial or clinical updates","bullets":["Presentation posted Oct 2, 2023, on Ovid investor relations website.","Slide titled 'Dawn of the neurotherapeutics era' by CEO Dr. Jeremy Levin.","Filing exhibit includes only the cover slide; no detailed data disclosed.","No material news regarding pipeline, financials, or guidance in this 8-K."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-050995","json":"https://secwatch.observer/filing/0000950170-23-050995.json","markdown":"https://secwatch.observer/filing/0000950170-23-050995.md","text":"https://secwatch.observer/filing/0000950170-23-050995.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000095017023050995/0000950170-23-050995-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000095017023050995/ovid-20231002.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T06:22:47.778457+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}